United States

Tim Dietlin joins as partner in Heidrick & Struggles' healthcare and life sciences practice

Friday, May 22, 2015 01:29 PM

Heidrick & Struggles, a provider of executive search, leadership consulting and culture shaping worldwide, has strengthened its healthcare and life sciences expertise among global practices by adding Tim Dietlin to the firm's Chicago office.

More... »

Quest Diagnostics

FDA approves Invega Trinza, only four-times-a-year treatment for schizophrenia

Thursday, May 21, 2015 02:27 PM

The FDA has approved under Priority Review Janssen Pharmaceuticals’ New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza. Invega Trinza, a three-month injection, is an atypical antipsychotic indicated to treat schizophrenia. Before starting Invega Trinza, patients must be adequately treated with Invega Sustenna (one-month paliperidone palmitate) for at least four months. Priority Review is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions.

More... »

Forum Pharmaceuticals relocates headquarters to Waltham, Massachusetts

Wednesday, May 20, 2015 03:15 PM

Forum Pharmaceuticals, a biopharmaceutical company focused on the development and delivery of innovative medicines to treat serious brain diseases, has relocated its corporate headquarters to a 112,500-square-foot, state-of-the-art facility located in Waltham, Mass. The move consolidates Forum’s operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Previously, Forum conducted business from two locations in Watertown, Mass. and Brighton, Mass. The company also maintains a small European office in the Netherlands.

More... »

CluePoints announces U.S patent allowance for SMART Engine

Monday, May 18, 2015 02:33 PM

CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has announced that the U.S. Patent and Trademark Office has granted a Notice of Allowance for Application No. 13/452,338, a patent which covers the company's SMART engine. The patent provides broad coverage for CluePoints' proprietary methodology that supports a risk-based approach to data monitoring in clinical trials.

More... »

Human Longevity, Cleveland Clinic collaborate on human genomics

Monday, May 18, 2015 01:04 PM

Human Longevity (HLI), a San Diego-based, privately held company building a comprehensive database of human genotypes and phenotypes, and the Cleveland Clinic, a nonprofit multispecialty academic medical center, have inked a broad collaboration agreement to first sequence and analyze blood samples from Cleveland Clinic's GeneBank study of de-identified patients.

More... »

OMT Therapeutics, Caltech ink UniRat alliance

Monday, May 18, 2015 01:01 PM

The California Institute of Technology (Caltech) has partnered with OMT Therapeutics, a private, California-based biotech company, to use OMT Therapeutics’ fully human nanobody platform, UniRat, for the generation of nanobodies against HIV-1.

More... »

23andMe launches Lupus research study in collaboration with Pfizer

Thursday, May 14, 2015 10:19 AM

23andMe, a personal genetics company based in Mountain View, Calif., has launched the Lupus Research Study in collaboration with Pfizer. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort also is in collaboration with the Lupus Research Institute and in concert with Lupus Awareness Month in May.

More... »

FPWR, NORD launch Global Prader-Willi Syndrome Registry

Monday, May 4, 2015 01:23 PM

The Foundation for Prader-Willi Research (FPWR), a nonprofit charitable organization, and National Organization for Rare Disorders (NORD), a nonprofit organization representing all patients and families affected by rare diseases in the U.S., have launched the Global Prader-Willi Syndrome Registry, a new database to accelerate research and cures for the rare disease Prader-Willi Syndrome (PWS).

More... »

FDA approves first generic Abilify to treat mental illnesses

Thursday, April 30, 2015 11:07 AM

Alembic Pharmaceuticals, Hetero LabsTeva Pharmaceuticals and Torrent Pharmaceuticals have received FDA approval to market generic Abilify (aripiprazole) in multiple strengths and dosage forms. Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. 

More... »

NIH names Dr. Eliseo Pérez-Stable director of the NIMHD

Thursday, April 30, 2015 10:47 AM

National Institutes of Health director Francis S. Collins, M.D., Ph.D., has announced the selection of Eliseo J. Pérez-Stable, M.D., as director of the National Institute on Minority Health and Health Disparities (NIMHD). Dr. Pérez-Stable is expected to join NIH in September.

More... »



May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs